ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. Clin Cancer Res. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Company Type For Profit. Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. View contacts for ImmunoMet Therapeutics to access new leads and connect with decision-makers. Chinatrust Executive House Hsin-Tien-New Taipei City Updated 2022 Room San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). I would also like to take the opportunity to sincerely thank Louise Peltier for her leadership over the last seven years and wish her well in her retirement., I am both honored and excited to be joining Immunomic Therapeutics at such a critical point in its growth cycle, said Ms. Harrison. Due to the volume of inquiries received, we regret that we cannot contact all applicants personally. Should we find that your skills and experience match our position needs, a Immunomic Therapeutics, Inc. representative will contact you to discuss the opportunity. Vaccine technology developed at Johns Hopkins could lead to - Hub While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). As a result, we make a significant investment in our employees through our Compensation, Health and Wellness, Retirement and Disability and Career Development programs. Description. Immunomic Therapeutics Stock Price, Funding, Valuation, Revenue Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. These factors are currently under intense focus in the cancer immunotherapy landscape. Internally, we are able to supply the R&D Team with UNITE products in a timely manner for their ongoing oncology studies. Immunomic Therapeutics Appoints Vice President, Cell Therapy For more information, please visit www.immunomix.com. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. The company was founded in 2005 and is based in Lancaster, Pennsylvania. amy@juniper-point.com mcarey@rxir.com Priscilla Fussell - Legal Counsel, Contracts & Intellectual Property Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. This feature is in beta and may change with future updates. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products . January 30, 2015 - Immunomic Therapeutics, Inc. ("Immunomic Therapeutics "), a company developing next generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive license agreement for Japan to . Immunomic Therapeutics Assumes Sponsorship of ATTAC II IND - Duke OTC Team - Immunomic Therapeutics aanagnostou@immunomix.com MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. Immunomic Therapeutics nucleic acid vaccines have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. Evaluate their financials based on Immunomic Therapeutics's post-money valuation and revenue. The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of. Contact Email info@immunomet.com. We have significant capabilities in molecular biology, including nucleic acid vaccine design, immunology, and tumor mouse modeling. 28 Employees . The Immunomic Therapeutics, Inc. team includes specialists in the areas of science, process development, engineering, production, marketing, finance, human resources, quality and regulatory, administrative support and more. Frans broad experience and deep knowledge in regulatory affairs will be a tremendous asset during a critical time for ITI, as we continue our interactions with the FDA and other key regulatory agencies regarding our clinical programs, stated William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. Over 100 studies have been published on LAMP, ranging from those focused on the fundamental biology of lysosomal associated membrane protein to the immunobiology of novel vaccine candidates. On behalf of the management team, I am pleased to welcome Ms. Harrison to ITI. Immunomic Therapeutics Announces the Appointment of Frances Harrison as Pancreatic cancer is the fourth-most-common cause of cancer-related mortality in the USA. Companies. ITI-1000 GBM - Cell Therapy. ITIs investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein, an endogenous protein in humans, for immune processing. 2015 Mar 19;519(7543):366-9. 2003 Sep 26;278(39):37926-36. Animal Health All. Company profile for HLB Co. Ltd. including key executives, insider trading, ownership, revenue and average growth rates. We provide a professional and challenging work environment . Immunic Therapeutics Company Profile: Stock Performance & Earnings Jan 2006 - Present17 years 2 months. Types of diversity represented in an organization, specifically of those who are founding members, currently the CEO, or have check-writing abilities in an investment firm. Immunomic Therapeutics' continued investment in Process Development provides value in several ways. ITI-2000 provides an UNITE platform address for HPV+ cancers. Very family oriented. Concurrent with the financing, five (5) members from HLB Co., LTD will be joining the Immunomic Therapeutics Board of Directors. Immunomic Therapeutics to Present at Biotech Showcase 2023, PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer, ITI Receives FDA Fast Track Designation for ITI-3000, ITI Announces Presentation on Nucleic Acid-Based UNITE Vaccine Platform at Vaccines Summit 2022. Company: Melissa Kemp Immunomic Therapeutics Mkemp@immunomix.com 301-968-3501 Media: Amy Conrad Juniper Point amy@juniper-point.com 858-366-3243 Contacts Companies - Johns Hopkins Technology Ventures The first ITI oncology clinical program was born as a result of this decision and each subsequent asset in the pipeline represents a natural transition from this original point of entry into oncology. Operating Status Active. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. Sampson and Mitchell in the development of a new approach to attack Glioblastoma Multiforme (GBM). A successful transition from cell to cell-free therapy would provide broad validation to the ITI pDNA pipeline. ICT has established a broad portfolio of CAR-T products to treat cancer patients. With HLBs support, we are well-positioned to accelerate our efforts in immuno-oncology, in particular glioblastoma multiforme, and rapidly advance other key candidates in our pipeline, including our most recent initiative into infectious diseases with development of our vaccine candidate for COVID-19.. Immunomic Therapeutics, Inc. | 2,335 followers on LinkedIn. ITI Company: Request a free trial. Contact Email info@immunic.de. The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. You can also compare prices and book all best hotels in New Taipei City with one-stop booking service on Trip.com. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy, and autoimmune diseases. We are pleased to welcome HLB as a significant shareholder of Immunomic Therapeutics and look forward to working with them within the framework of the HLB Bio family of companies. News | Astellas Pharma Inc. They have a proven track record of success in Asia and share our commitment and passion for developing best-in-class therapies for cancer and other serious diseases, said Dr. William Hearl, CEO of Immunomic Therapeutics. Nature. Mohan Karkada - Director of Research and Development - LinkedIn Mr. Stamper holds a Master of Biotechnology Enterprise and Entrepreneurship Degree (MBEE) from Johns Hopkins University, a Master of Science Degree in Biologics Engineering from Purdue University, and a Bachelor of Science Degree in Biochemistry from Indiana University. While induction of tumor-reactive CD8+ T cells is a major goal of cancer therapy, CD4+ T cells provide essential support to CD8+ T cells by promoting their expression of cytotoxic effector molecules and increasing their migratory capacity. Glioblastoma Multiforme (GBM) - Immunomic Therapeutics ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics. Immunomic Therapeutics Announces Presentation on Nucleic Acid-Based The antigens mainly elicits TH1 response leading to cytokine release, development of cytotoxic CD8 T cells and memory CD4 T cells. Hope versus experience in glioblastoma | Evaluate In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. Active, Closed, Last funding round type (e.g. 2017 Apr 15;23(8):1898-1909. Our portfolio includes more than 150 disruptive companies in areas ranging from the life sciences to engineering technology and digital health. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. Stock ticker symbol (e.g. 301-968-3501 A $300 million worldwide licensing agreement announced last week between Immunomic Therapeutics and Astellas Pharma to develop treatment for a wide range of allergic diseases, including peanut allergies, is the largest deal ever to come out of Johns Hopkins Technology Ventures, the patent, licensing, and technology . ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. ITI Company: Chief Scientific Officer (CSO) Immunomic Therapeutics, Inc. Jun 2019 - Present3 years 9 months. 1K followers 500+ connections. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. 2017 Jun 12:1-10. Preclinical data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. Home - Immunomic Therapeutics ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein)-mediated nucleic acid-based immunotherapy, today announced the appointment of Frances Harrison as Senior Vice President, Regulatory Affairs. ITI Company: 917-322-2571, Internet Explorer presents a security risk. Immunomic Therapeutics investigational UNITEplatform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. It is interesting to note that the emerging market of brain tumor includes budding gene therapies, i.e., Ofranergene obadenovec (VBL Therapeutics) and Ad-RTS-hIL-12 in combination with Veledimex . April 23, 2020 04:00 PM Eastern Daylight Time. Immunomic Therapeutics is a biotech company committed to patients. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. Find More Contacts for Immunic Therapeutics, Edit Lists Featuring This Company Section, Immunic, Inc. 15010 Broschart Road Suite 250. Immunomic Therapeutics, Inc. Pays for all health and welfare insurance premiums 100%. The initial foray into immuno-oncology was undertaken when ITI decided to support the work of Drs. Director of Research and Development at Immunomic Therapeutics, Inc. - most recent Rockville, Maryland, United States. We provide a professional and challenging work environment where employees can grow and share in the continued success of the company. Find all information and best deals of Chinatrust Executive House Hsin-Tien, New Taipei City on Trip.com! ITI-2000 HPV+ Tumors. 2016;2016:4857869. Headquarters Location. Proceeds from the financing will support the acceleration of ITI's Phase II clinical trial of ITI-1000 for the treatment of glioblastoma multiforme (GBM), advance its emerging pipeline, and expand upon the current applications of its UNITE platform. GBM patients white blood cells are removed, matured into dendritic cells and vaccinated against the pp65 viral protein, then returned to the patient. Since the Astellas deals, we have nearly doubled our research team to include deeper oncology expertise, including vaccinology, even neoantigen vaccine specialization. Company profile page for Immunomic Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information All answers shown come directly from Immunomic Therapeutics Reviews and are not edited or altered. No.93, Zhongyang Rd., Xindian Dist., New Taipei City 231, Taiwan. Immunic Therapeutics Investments & Acquisitions (2) Company Name Deal Date Deal Type Deal Size Industry Lead Partner; 00000 0000000: 12-Apr-2019: 0000000000: Drug Discovery: 000000 00: 4SC (immunology portfolio) 28-Sep-2016: ITI-3000 is a plasmid DNA vaccine targeting the large T antigen (LT) of Merkel cell polyomavirus (MCPyV). To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. 15010 Broschart Dr., Suite 110, Rockville, MD 20850. Immunomic Therapeutics - Products, Competitors, Financials, Employees Our goal is to overcome the limitations of current immuno-oncology therapies by . GOLDEN, Colo. December 13, 2022 PharmaJet, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with ITI maintains its headquarters in Rockville, Maryland. Immunomic Therapeutics Announces Close of $61.3M Financing Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bo dy's natural biochemistry to develop . Immunomic Therapeutics nucleic acid vaccines have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. News Releases | PharmaJet The foundation of a successful company is only as strong as the quality of its employee team. UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus. Melody Carey J Biol Chem. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. Working at Immunomic Therapeutics | Glassdoor Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. Great people . J Immunol Res. / Oct 13, 2015. ITI-1000 is a dendritic cell therapy comprised of autologous dendritic cells (DCs) loaded with messenger ribonucleic acid (mRNA) encoding the human Lysosomal Associated Membrane Protein (hLAMP) gene fused in frame to a human Cytomegalovirus (hCMV) matrix protein, pp65 gene (hLAMP:pp65) and subsequently administered with Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Tetanus/diphtheria (Td) toxoid which serve as adjuvants. Brians specific and deep knowledge of cell therapy manufacturing and operations will be invaluable as we prepare for phase 3 testing of ITI-1000, our lead dendritic cell therapy for the treatment of glioblastoma multiforme (GBM).. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. View detailed 028300.KR description & address. Work Here? The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. Batich, K.A., Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. We currently have 4 wholly-owned oncology programs, with our lead program in Phase 2 clinical studies for GBM. Innovative Cellular Therapeutics (ICT) | LinkedIn Prior to joining ITI, Mr. Stamper held director roles in manufacturing at Kite Pharma, a global biopharmaceutical company whose focus is cell therapy to treat and cure cancer.
Cliff Robertson Cause Of Death,
How Many Hurricanes Have Hit Cape Canaveral,
Articles I